MAX
Company Analysis Ascentage Pharma Group International
1. Summary
Advantages
- Price (8.48 $) is less than fair price (8.87 $)
- The stock's return over the last year (45.58%) is higher than the sector average (-4.41%).
Disadvantages
- Dividends (0%) are below the sector average (481.23%).
- Current debt level 63.74% has increased over 5 years from 30.25%.
- The company's current efficiency (ROE=-249.8%) is lower than the sector average (ROE=14.38%)
Similar companies
2. Share price and performance
2.1. Share price
2.3. Market efficiency
| Ascentage Pharma Group International | Index | ||
|---|---|---|---|
| 7 days | 0% | 14.9% | -0.7% |
| 90 days | 0% | 0.1% | -3.7% |
| 1 year | 45.6% | -4.4% | 13.9% |
ASPHF vs Sector: Ascentage Pharma Group International has outperformed the "" sector by 49.99% over the past year.
ASPHF vs Market: Ascentage Pharma Group International has outperformed the market by 31.71% over the past year.
Stable price: ASPHF is not significantly more volatile than the rest of the market on "USA Stocks" over the last 3 months, with typical variations of +/- 5% per week.
Long period: ASPHF with weekly volatility of 0.88% over the past year.
3. Summary of the report
5. Fundamental Analysis
5.1. Stock price and price forecast
Below fair price: The current price (8.48 $) is lower than the fair price (8.87 $).
Price not significantly lower than the fair price: The current price (8.48 $) is slightly lower than the fair price by 4.6%.
5.2. P/E
P/E vs Sector: The company's P/E (-4.25) is lower than that of the sector as a whole (204.11).
P/E vs Market: The company's P/E (-4.25) is lower than that of the market as a whole (184.98).
5.3. P/BV
P/BV vs Sector: The company's P/BV (21.2) is higher than that of the sector as a whole (6.77).
P/BV vs Market: The company's P/BV (21.2) is lower than that of the market as a whole (26.77).
5.3.1 P/BV Similar companies
5.5. P/S
P/S vs Sector: The company's P/S indicator (5.93) is lower than that of the sector as a whole (11.93).
P/S vs Market: The company's P/S indicator (5.93) is lower than that of the market as a whole (20.5).
5.5.1 P/S Similar companies
5.5. EV/Ebitda
EV/Ebitda vs Sector: The company's EV/Ebitda (-26.28) is lower than that of the sector as a whole (2.06).
EV/Ebitda vs Market: The company's EV/Ebitda (-26.28) is lower than that of the market as a whole (35.22).
6. Profitability
6.1. Profitability and revenue
6.2. Earnings per share - EPS
6.3. Past profitability Net Income
Yield Trend: Negative and has fallen by -9.64% over the last 5 years.
Accelerating profitability: The return for the last year (0%) exceeds the average return for 5 years (-9.64%).
Profitability vs Sector: The return for the last year (0%) is lower than the return for the sector (149.73%).
6.4. ROE
ROE vs Sector: The company's ROE (-249.8%) is lower than that of the sector as a whole (14.38%).
ROE vs Market: The company's ROE (-249.8%) is lower than that of the market as a whole (137.87%).
6.6. ROA
ROA vs Sector: The company's ROA (-15.84%) is lower than that of the sector as a whole (1.42%).
ROA vs Market: The company's ROA (-15.84%) is lower than that of the market as a whole (124.61%).
6.6. ROIC
ROIC vs Sector: The company's ROIC (0%) is lower than that of the sector as a whole (0%).
ROIC vs Market: The company's ROIC (0%) is lower than that of the market as a whole (8.35%).
Pay for your subscription
More functionality and data for company and portfolio analysis is available by subscription
8. Dividends
8.1. Dividend yield vs Market
Low yield: The dividend yield of the company 0% is below the average for the sector '481.23%.
8.2. Stability and increase in payments
Unstable dividends: The company's dividend yield 0% has not been consistently paid over the past 7 years, DSI=0.
Weak dividend growth: The company's dividend yield 0% has been growing weakly or stagnant over the past 5 years. Growth over only 0 years.
8.3. Payout percentage
Dividend Coverage: Current payments from income (0%) are at an uncomfortable level.
Based on sources: porti.ru
